Roquefort Therapeutics (LON:ROQ) Trading 12% Higher – What’s Next?

Roquefort Therapeutics plc (LON:ROQ)’s stock price traded up 12% during trading on Tuesday . The company traded as high as GBX 4.20 ($0.05) and last traded at GBX 4.20 ($0.05). 1,302,970 shares were traded during trading, a decline of 0% from the average session volume of 1,308,735 shares. The stock had previously closed at GBX 3.75 ($0.05).

Roquefort Therapeutics Stock Up 12.0 %

The company has a market cap of £5.42 million, a P/E ratio of -420.00 and a beta of 0.05. The company’s 50-day moving average is GBX 4.05 and its two-hundred day moving average is GBX 4.04. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.